
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Imaging, Diagnosis, Prognosis |
1 Children's Medical Research Institute; 2 Royal Prince Alfred Hospital; 3 Children's Hospital Westmead; 4 Royal North Shore Hospital, University of Sydney; and 5 Douglass Hanly Moir Pathology, Sydney, New South Wales, Australia; 6 MD Anderson Cancer Center, Houston, Texas; 7 University of Otago, Dunedin, New Zealand; 8 Royal Hallamshire Hospital, Sheffield, United Kingdom; 9 University of Iowa, Iowa City, Iowa; and 10 Department of Pathology, St Vincent's Hospital, Catholic University, Suwon, Kyungkido, South Korea
Requests for reprints: Roger Reddel, Children's Medical Research Institute, 214 Hawkesbury Road, Westmead, New South Wales 2145, Australia. Phone: 61-2-96872800; Fax: 612-968-72120; E-mail:rreddel{at}cmri.usyd.edu.au.
Purpose and Experimental Design: Telomeres of tumor cells may be maintained by telomerase or by alternative lengthening of telomeres (ALT). The standard ALT assay requires Southern analysis of high molecular weight genomic DNA. We aimed to establish and validate an ALT assay suitable for archived paraffin-embedded tumors and to use it to examine the prevalence and clinical significance of ALT in various types of tumors that are often telomerase negative.
Results: To assay for ALT, we detected ALT-associated promyelocytic leukemia (PML) bodies (APBs) by combined PML immunofluorescence and telomere fluorescence in situ hybridization. APBs are PML nuclear domains containing telomeric DNA and are a known hallmark of ALT in cell lines. The APB assay concurred with the standard ALT assay in 62 of 62 tumors and showed that 35% of 101 soft tissue sarcomas (STS), 47% of 58 osteosarcomas (especially younger patients), 34% of 50 astrocytomas, and 0% of 17 papillary thyroid carcinomas were ALT positive (ALT+). The prevalence of ALT varied greatly among different STS subtypes: malignant fibrous histiocytomas, 77%; leiomyosarcomas, 62%; liposarcomas, 33%; synovial sarcomas, 9%; and rhabdomyosarcomas, 6%. ALT correlated with survival in glioblastoma multiforme and occurred more often in lower-grade astrocytomas, but ALT+ and ALT sarcomas were equally aggressive in terms of grade and clinical outcome.
Conclusion: The APB assay for ALT is suitable for paraffin-embedded tumors. It showed that a substantial proportion of STS, osteosarcomas, and astrocytomas, but not papillary thyroid carcinomas use ALT. APB positivity correlated strongly with survival of patients with astrocytomas.
Key Words: ALT-associated PML body soft tissue sarcoma osteosarcoma glioblastoma multiforme papillary carcinoma of thyroid
This article has been cited by other articles:
![]() |
R. Villa, M. G. Daidone, R. Motta, L. Venturini, C. De Marco, A. Vannelli, S. Kusamura, D. Baratti, M. Deraco, A. Costa, et al. Multiple Mechanisms of Telomere Maintenance Exist and Differentially Affect Clinical Outcome in Diffuse Malignant Peritoneal Mesothelioma Clin. Cancer Res., July 1, 2008; 14(13): 4134 - 4140. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Else, T. J. Giordano, and G. D. Hammer Evaluation of Telomere Length Maintenance Mechanisms in Adrenocortical Carcinoma J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1442 - 1449. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Bernardo, N. Zaffaroni, F. Novara, A. M. Cometa, M. A. Avanzini, A. Moretta, D. Montagna, R. Maccario, R. Villa, M. G. Daidone, et al. Human Bone Marrow Derived Mesenchymal Stem Cells Do Not Undergo Transformation after Long-term In vitro Culture and Do Not Exhibit Telomere Maintenance Mechanisms Cancer Res., October 1, 2007; 67(19): 9142 - 9149. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Compton, J.-H. Choi, A. J. Cesare, S. Ozgur, and J. D. Griffith Xrcc3 and Nbs1 Are Required for the Production of Extrachromosomal Telomeric Circles in Human Alternative Lengthening of Telomere Cells Cancer Res., February 15, 2007; 67(4): 1513 - 1519. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Costa, M. G. Daidone, L. Daprai, R. Villa, S. Cantu, S. Pilotti, L. Mariani, A. Gronchi, J. D. Henson, R. R. Reddel, et al. Telomere Maintenance Mechanisms in Liposarcomas: Association with Histologic Subtypes and Disease Progression. Cancer Res., September 1, 2006; 66(17): 8918 - 8924. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-J. Chen, V. Hakin-Smith, M. Teo, G. E. Xinarianos, D. A. Jellinek, T. Carroll, D. McDowell, M. R. MacFarlane, R. Boet, B. C. Baguley, et al. Association of Mutant TP53 with Alternative Lengthening of Telomeres and Favorable Prognosis in Glioma. Cancer Res., July 1, 2006; 66(13): 6473 - 6476. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Muntoni and R. R. Reddel The first molecular details of ALT in human tumor cells Hum. Mol. Genet., October 15, 2005; 14(suppl_2): R191 - R196. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Johnson, R. J. Varkonyi, J. Schwalm, R. Cragle, A. Klein-Szanto, A. Patchefsky, E. Cukierman, M. von Mehren, and D. Broccoli Multiple Mechanisms of Telomere Maintenance Exist in Liposarcomas Clin. Cancer Res., August 1, 2005; 11(15): 5347 - 5355. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. N. Jeyapalan, H. Varley, J. L. Foxon, R. E. Pollock, A. J. Jeffreys, J. D. Henson, R. R. Reddel, and N. J. Royle Activation of the ALT pathway for telomere maintenance can affect other sequences in the human genome Hum. Mol. Genet., July 1, 2005; 14(13): 1785 - 1794. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Linardic, D. L. Downie, S. Qualman, R. C. Bentley, and C. M. Counter Genetic Modeling of Human Rhabdomyosarcoma Cancer Res., June 1, 2005; 65(11): 4490 - 4495. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |